China is set to become the third Earth nation to successfully land an object on the surface of the Moon later this weekend.
Mike Gallagher is the leader of the game industry’s trade group. We hope to learn from his insights at GamesBeat 2013.
Activision rejoins the ESA, while China’s Tencent joins for the first time.
Physical activity is a feature in 20 percent of video games now.
It’s been a really good week for space programs across the world.
The $67 billion worldwide video game industry is breaking through barriers on the cultural, legal and political fronts, according to the annual report of the Entertainment Software Association, the U.S. industry’s trade group.
For years, the Electronic Entertainment Expo (E3) has been associated with the city of Los Angeles and its sprawling downtown convention center. But the game industry trade group is considering moving out because of construction issues.
An estimated 45,000 people are going to attend the Electronic Entertainment Expo (E3) this week at the Los Angeles Convention Center in downtown L.A.
Trade associations are weighing in on the delay of the vote on the Stop Online Privacy Act — a delay that may have effectively killed the anti-piracy legislation.
The video game industry’s E3 Expo starts on Sunday evening in Los Angeles next week. This is the conference where all of the cool new games are announced. While it lost its way in the past, last year’s show was a big success, with more than 40,000 attendees. And it looks like this one will be bustling as well. We talked about the conference and industry issues with Mike Gallagher, president and chief executive of the Entertainment Software Association, which puts on E3.
Is the bell tolling for EPO? – The news keeps going from bad to worse for the wonder drugs of biotech — the anemia treatments known as ESAs or EPO, shorthand for “erythropoiesis stimulating agents” and “erythropoietin,” respectively. Earlier today, an FDA advisory panel recommended new warnings for the drugs, which stimulate the production of oxygen-carrying red blood cells, as well as fresh clinical studies on their safety. Recent studies in kidney-dialysis patients linked higher doses of ESAs to heart problems and strokes, while studies in cancer patients treated for chemotherapy-related anemia have suggested that the treatments don’t improve patient survival, and may even cut lives short — possibly by encouraging tumor growth.